A compound represented by formula, a geometric or stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein, T 1, T 2, T 3, T 4, T 5, and T 6 are each independently selected from the group consisting of CR 3 and N; W is selected from the group consisting of CR 4 and N; X 1 and X 2 are each independently CR 5 R 6; Ri is selected from the group consisting of H, F, Cl, Br, I, OH, NH 2, CN and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R a; R 2 is selected from the group consisting of H and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R b; R 3 and R 4 are each independently selected from the group consisting of H, F, Cl, Br, I, OH and NH 2; R 5 and R 6 are each independently selected from the group consisting of H, F, Cl, Br, I, OH, NH 2 and C 1-6 alkyl; Li is selected from the group consisting of -C 1-3 alkyl-, -C 3-6 cycloalkyl- and -4- to 6-membered heterocycloalkyl-, wherein the -C 1-3 alkyl-, -C 3-6 cycloalkyl- and -4- to 6-membered heterocycloalkyl- are optionally substituted by 1, 2 or 3 R c; L 2 is selected from the group consisting of-C 1-3 alkyl-, -C 1-3 alkyl-O-, -N(R d)-, -C 1-3 alkyl-N(R d)- and -O-; R a is independently selected from the group consisting of H, F, Cl, Br, I, OH and NH 2; R b is selected from the group consisting of H, F, Cl, Br, I, OH and NH 2; R c is selected from the group consisting of H, F, Cl, Br, I, OH, NH 2, CN, C 1-3 alkyl and C 1-3 alkyl-C=O-, wherein the C 1-3 alkyl and C 1-3 alkyl-C=O- are optionally substituted by 1, 2 or 3 R; R d is selected from the group consisting of H and C 1-3 alkyl; R is independently selected from the group consisting of F, Cl, Br, I, OH and NH 2; the carbon atom marked with "*" is a chiral carbon atom present in a single enantiomer form of or or in a form enriched in one enantiomer; the 4- to 6-membered heterocycloalkyl independently comprises 1, 2, 3 or 4 heteroatoms or heteroatomic groups independently selected from the group consisting of -NH-, -O-, -S- and N. T 1, T 2, T 3, T 4, T 5, and T 6 are each independently selected from the group consisting of CR 3 and N; W is selected from the group consisting of CR 4 and N; X 1 and X 2 are each independently CR 5 R 6; Ri is selected from the group consisting of H, F, Cl, Br, I, OH, NH 2, CN and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R a; R 2 is selected from the group consisting of H and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R b; R 3 and R 4 are each independently selected from the group consisting of H, F, Cl, Br, I, OH and NH 2; R 5 and R 6 are each independently selected from the group consisting of H, F, Cl, Br, I, OH, NH 2 and C 1-6 alkyl; Li is selected from the group consisting of -C 1-3 alkyl-, -C 3-6 cycloalkyl- and -4- to 6-membered heterocycloalkyl-, wherein the -C 1-3 alkyl-, -C 3-6 cycloalkyl- and -4- to 6-membered heterocycloalkyl- are optionally substituted by 1, 2 or 3 R c; L 2 is selected from the group consisting of-C 1-3 alkyl-, -C 1-3 alkyl-O-, -N(R d)-, -C 1-3 alkyl-N(R d)- and -O-; R a is independently selected from the group consisting of H, F, Cl, Br, I, OH and NH 2; R b is selected from the group consisting of H, F, Cl, Br, I, OH and NH 2; R c is selected from the group consisting of H, F, Cl, Br, I, OH, NH 2, CN, C 1-3 alkyl and C 1-3 alkyl-C=O-, wherein the C 1-3 alkyl and C 1-3 alkyl-C=O- are optionally substituted by 1, 2 or 3 R; R d is selected from the group consisting of H and C 1-3 alkyl; R is independently selected from the group consisting of F, Cl, Br, I, OH and NH 2; the carbon atom marked with "*" is a chiral carbon atom present in a single enantiomer form of or or in a form enriched in one enantiomer; the 4- to 6-membered heterocycloalkyl independently comprises 1, 2, 3 or 4 heteroatoms or heteroatomic groups independently selected from the group consisting of -NH-, -O-, -S- and N.